Genomic features of lung cancer patients in Indonesia’s national cancer center

Author:

Hanafi Arif Riswahyudi,Hanif Muhammad Alfin,Pangaribuan Mariska T.G.,Ariawan Wily Pandu,Sutandyo Noorwati,Kurniawati Sri Agustini,Setiawan Lyana,Cahyanti Dian,Rayhani Farilaila,Imelda Priscillia

Abstract

Abstract Introduction Advances in molecular biology bring advantages to lung cancer management. Moreover, high-throughput molecular tests are currently useful for revealing genetic variations among lung cancer patients. We investigated the genomics profile of the lung cancer patients at the National Cancer Centre of Indonesia. Methods A retrospective study enrolled 627 tissue biopsy samples using real time polymerase chain reaction (RT-PCR) and 80 circulating tumour DNA (ctDNA) liquid biopsy samples using next-generation sequencing (NGS) from lung cancer patients admitted to the Dharmais Cancer Hospital from January 2018 to December 2022. Data were obtained from medical records. Data statistically analysed with p < 0.05 is considered significant. Result The EGFR test results revealed by RT-PCR were wild type (51.5%), single variant (38.8%), double variant (8.3%), and triple variant (1.4%), with 18.66% L85R, 18.22% Ex19del, and 11.08% L861Q variant. Liquid biopsy ctDNA using NGS showed only 2.5% EGFR wild type, 62.5% single variant and 35% co-variant, with EGFR/TP53 and EGFR/PIK3CA as the highest. Conclusion EGFR variants are the most found in our centre. Liquid biopsy with ctDNA using NGS examination could detect broad variants and co-variants that will influence the treatment planning.

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Reference61 articles.

1. Global Cancer Observatory (gco.iacr.fr) [Internet]. Lyon: International Agency for Research of Cancer; 2022. Cancer today pie chart: Estimated number of new cases in 2020 worldwide, both sexes, all ages. Available from: Cancer Today (iarc.fr). Accessed on August 22, 2023.

2. World Health Organization. Indonesia [Internet]. World Health Organization; 2021. p1–2. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf. Accessed on August 22, 2023.

3. Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82(11):801–11. https://doi.org/10.1016/j.humimm.2021.02.012.

4. Sabour L, Sabour M, Ghorbian S. Clinical applications of next-generation sequencing in Cancer diagnosis. Pathol Oncol Res. 2017;23(2):225–34. https://doi.org/10.1007/s12253-016-0124-z.

5. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3